Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

1636

Accredited to ISO/IEC 17025:2017

Drug Control Centre – King's College London

Issue No: 054 **Issue date:** 04 November 2026

The Franklin-Wilkins Building
150 Stamford Street
London
SE1 9NH
United Kingdom

Contact: Kim Wolff
Tel: +44 (0)20 7848 4850
E-Mail: Kim.Wolff@kcl.ac.uk
Website: www.kcl.ac.uk/dcc

Testing performed at the above address only

DETAIL OF ACCREDITATION

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
BODY FLUIDS	Physical - Chemical Analysis	Documented In house methods in accordance with WADA International Standard for Laboratories (ISL)
Human Urine	pH	Sample integrity check using pH strips (SOP9)
	Specific gravity	Sample Integrity check using refractometer (SOP9)
	Chemical Analysis	
Human Urine	Initial Testing Procedures and Qualitative Confirmation Procedures of substances prohibited by the World Anti Doping Agency (WADA) Including: S0 Non-approved Substances. S1 Anabolic agents (including 19-norandrosterone) S3 Beta-2 Agonists (b2ag) S2 Peptide hormones, growth factors, related substances and mimetics S4 Hormone and metabolic modulators S5 Diuretics and other masking agents, including plasma expanders M1 Manipulation of Blood and Blood Components (e.g. Efaproxiral RSR13) S6 Stimulants S7 Narcotics S8 Cannabinoids S9 Glucocorticoids P1 Beta Blockers	Flexible scope (SOP13) using LC and GC coupled to mass spectrometry e.g. LC-MS, GC-MS, LCMS/MS, GCMS/MS, using procedures SOP4, SOP5, SOP6,SOP18
	Alcohol Markers: (Ethyl glucuronide, Ethyl Sulphate)	LC-MS (SOP6)

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
BODY FLUIDS (cont'd)	Chemical Analysis (cont'd)	Documented In house methods In accordance with WADA International Standard for Laboratories (ISL)
	Initial Testing Procedures and Qualitative Confirmation Procedures of substances prohibited by the World Anti Doping Agency (WADA)Including:	Using Immunopurification, gel electrophoresis with immunoblotting and luminescence detection e.g. Sarcosyl PAGE
Human Urine and Blood (Serum)	S2 Erythropoietins and agents affecting erythropoiesis e.g. Erythropoeitin (EPO), darbepoetin (dEPO), CERA (Continuous Erythropoiesis Receptor Activator)	Immunopurification, gel electrophoresis with immunoblotting and luminescence detection e.g. Sarcosyl PAGE (SOP20)
Human Urine	S2 Human chorionic gonadotrophin (hCG) – Screening only.	Chemiluminescence (Immulite) for total hCG (SOP7)
	S2 Luteinizing Hormone	Immunoassay; Chemiluminescence (Immulite) (SOP7)
Human Urine	Initial Testing Procedures and Qualitative Confirmation Procedures of substances prohibited by the World Anti Doping Agency (WADA)Including:	Using gas chromatography coupled to mass spectrometry (GC-MS and GC-MS/MS) and Gas Chromatography Combustion Isotope Ratio Mass Spectrometry (GC-C-IRMS)
	S1 Anabolic agents such as; Testosterone Epitestosterone including determination of T/E ratio (endogenous steroid profile)	GC-MS, GC-MS/MS, GC-C-IRMS (SOP5), (SOP11)
Blood (Serum)	Initial Testing Procedures and Qualitative Confirmation Procedures of substances prohibited by the World Anti Doping Agency (WADA) Including:	Flexible scope (SOP13) using liquid chromatography coupled to mass spectrometry (LC-MS and LC-MS/MS

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
BODY FLUIDS (cont'd)	Chemical Analysis (cont'd)	Documented In house methods In accordance with WADA International Standard for Laboratories (ISL)
Human Urine	Initial Testing Procedures and Qualitative Confirmation Procedures of substances prohibited by the World Anti Doping Agency (WADA) Including:	Flexible scope (SOP13) using liquid chromatography coupled to mass spectrometry (LC-MS and LC-MS/MS
	S2 Peptide hormones, Growth Factors, related substances and mimetics (e.g. Growth Hormone Releasing Factors)	LC-MS and LC-MS/MS (SOP18)
Human Urine	Quantitative Confirmation Procedures of threshold substances prohibited by the World Anti Doping Agency (WADA):	
	Salbutamol	liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)
	Formoterol	liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)
	Cathine	liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)
	Ephedrine	liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)
	Methylephedrine	liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)
	Pseudoephedrine	liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)
	Morphine	liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
BODY FLUIDS (cont'd)	Chemical Analysis (cont'd)	Documented In house methods In accordance with WADA International Standard for Laboratories (ISL)
Human Urine	Quantitative Confirmation Procedures of threshold substances prohibited by the World Anti Doping Agency (WADA):	
	Carboxy THC	Gas chromatography coupled to mass spectrometry (GC-MS/MS) (SOP6)
Human Blood (Serum)	Initial Testing Procedures and Quantitative Confirmation Procedures:	
	S2 Peptide hormones, Growth Factors, related substances and mimetics Human Growth Hormone (hGH) isoform ratio HGH biomarkers (IGF- I and P-III-NP) measurement	Immunoassay: Luminescence detection Radioimmunoassay (SOP19)
	Initial Testing and Confirmation Procedures	
Human Blood (Serum)	Endocrine Moduel: Direct quantitative measurement of Insulin-like Growth Factor (IGF-1) through intact (top-down) measurement (Range 50 to1000 ng/ml)	liquid chromatography coupled to mass spectrometry (LC-MS-MS) (SOP19)
Dry Blood Spots	Initial Testing Procedures and Qualitative Confirmation Procedures	Flexible scope (SOP13) using Gas chromatography coupled to mass spectrometry (GC-MS/MS) SOP24-01
	Anabolic Steroids	
	Small Molecules	Flexible scope (SOP13) using liquid chromatography coupled to mass spectrometry (LC-MS/MS) SOP24-03 and SOP24-04

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
BODY FLUIDS (cont'd)	Chemical Analysis (cont'd)	Documented In house methods In accordance with WADA International Standard for Laboratories (ISL)
Human Blood	Haemetalogical Module: Blood parameters: Haemoglobin concentration Percentage of reticulocytes Number of red blood cells (erythrocytes), Number of platelets, Number of reticulocytes, Number of all white blood cells (leucocytes), Haematocrit (erythrocyte ratio of total blood volume) Mean cell (erythrocyte) volume in total sample, Mean haemoglobin volume per Number of all red blood cells, Mean cell (erythrocyte) haemoglobin concentration)	Flow Cytometry (SOP17)
Human Blood (Plasma and Serum)	Initial Testing Procedures: Detection of haemoglobin- based oxygen carriers (HBOCs)	Sysmex XN-1000 haematological analyser (SOP17-02)
Human Blood (Serum)	Initial and ConfirmatoryTesting Procedures: Steroid Esters	Flexible scope (SOP13) using liquid chromatography coupled to mass spectrometry (LC-MS and LC-MS/MS Liquid chromatography mass spectrometry (LCMSMS) SOP 25-02; SOP 25-03
Human Blood (Serum)	Initial Testing Procedures and Quantitative Confirmation Procedures of Blood Steroid Markers	Flexible scope (SOP013) using liquid-liquid extraction (LLE), followed by liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP026)
END		